Preclincial Testing of Sorafenib and RAD001 in the Nf fl/fl;DhhCre mouse model of plexiform neurofibroma using magnetic resonance imaging

摘要

BackgroundNeurofibromatosis type 1 (NF1) is an inherited disease predisposing affected patients to variable numbers of benign neurofibromas. To date there are no effective chemotherapeutic drugs available for this slow growing tumor. Molecularly targeted agents that aim to slow neurofibroma growth are being tested in clinical trials. So preclinical models for testing potential therapies are urgently needed to prioritize drugs for clinical trials of neurofibromas.